Programming – Vascular Discovery 2025
Marriott Baltimore Waterfront | Baltimore, Maryland
Vascular Discovery 2025 Schedule-at-a-Glance
| Time | Activity |
|---|---|
| 8:00 a.m. to 6:00 p.m. | Vascular Research Initiatives Conference (VRIC) This event is not part of the official Vascular Discovery Scientific Sessions as planned by the Program Committee. Separate registration is required to attend. |
| 3:00 p.m. to 7:00 p.m. | Vascular Discovery Scientific Sessions Registration |
| 6:00 p.m. to 8:00 p.m. | Poster Session 1 & Reception |
| Time | Activity |
|---|---|
| 7:00 a.m. | Registration and Exhibits |
| 7:00 a.m. to 8:00 a.m. | Morning Coffee |
| 7:00 a.m. to 8:00 a.m. | Early Career Training Session 1 |
| 8:00 a.m. to 8:30 a.m. |
Conference Opening Welcome 8:00 Welcome Remarks from AHA President 8:15 Welcome Remarks from the Program Chair |
| 8:30 a.m. to 10:00 a.m. |
Plenary Session 1: Hot Topics in Cardiovascular Disease 8:30 Diabetes-Associated Heart Disease: Bridging the Gap between Basic and Translational Research 9:00 Title TBA 9:30 Keynote Lecture: TBA |
| 10:00 a.m. to 10:30 a.m. | BREAK/Exhibits |
| 10:30 a.m. to 12:00 p.m. |
Concurrent Session 1a:Therapeutic Targets in Cardiovascular Disease 10:30 Title TBA 11:00 TBA 11:30 Oral Abstract 1 |
| 10:30 a.m. to 12:00 p.m. |
Concurrent Session 1b: Thrombosis: Signaling, Mechanisms & Function 10:30 Mitochondrial Dynamics Shape Platelet Function, Hemostasis and Thrombosis |
| 12:00 p.m. to1:30 p.m. | The Mentor of Women Award Luncheon - Presented by the ATVB Women's Leadership Committee (ticket required) or or |
| 1:30 p.m.to 3:00 p.m. | Plenary Session 2: Highlights from the ATVB Journal |
| 3:00 p.m. to 3:30 p.m. | Break/Exhibits |
| 3:30 p.m. to 5:00 p.m. |
Concurrent Session 2a: Shobha Ghosh Investigator in Training Award Competition & Nano Talks |
| 3:30 p.m. to 5:00 p.m. |
Concurrent Session 2b: Metabolism in Cardiovascular Disease 3:30 Title: TBA 4:00 Title: TBA 4:30 Oral Abstract 1 |
| 5:00 p.m to 7:00 p.m. |
Poster Session 2 & Reception |
| Time | Activity |
|---|---|
| 7:00 a.m. | Registration and Exhibits |
| 7:00 a.m. to 8:00 a.m. | Morning Coffee |
| 7:00 a.m. to 8:00 a.m. | Early Career Training Session 2 |
| 7:00 a.m. to 8:00 a.m. | Industry Event #1 (in the concurrent room) |
| 8:00 a.m. to 9:30 a.m. |
Plenary Session 3: Inflammation in Cardiovascular Diseases 8:00 Brain-Body Communication Regtulating Inflammation in Cardiovascular Disease 8:30 Title TBA 9:00 Title TBA |
| 9:30 a.m. to 10:00 a.m. | BREAK/Exhibits |
| 10:00 a.m. to 11:30 a.m. |
Concurrent Session 3a: Apolipoproteins, Lipoproteins, and Lipid Mechanism 10:30 Title TBA |
| 10:00 a.m. to 11:30 a.m. |
Concurrent Session 3b: Translational Studies in Vascular Disease
11:00 Oral Abstract 1 |
| 11:30 a.m. to 1:00 p.m. |
Diversity Event (Presented by the ATVB Diversity Committee) - ticketed event |
| 11:30 a.m. to 1:00 p.m. |
Lunch on Your Own |
| 12:00 p.m. to 1:00 p.m. | Industry Event #2 (in concurrent room) |
| 1:00 p.m. to 3:00 p.m. | Plenary Session 4: Early Career Investigator Award Competition Irvine H. Page Junior Faculty Research Award Kenneth M. Brinkhous Early Career Investigator Award in Thrombosis |
| 3:00 p.m. to 3:30 p.m. | Break/Exhibits |
| 3:30 p.m to 5:00 p.m. |
Concurrent Session 4a: Mechanisms of Atherosclerosis, Inflammation & Immunity in the Vessel Wall 3:30 Title TBA 4:30 Oral Abstract 1 |
| 3:30 p.m to 5:00 p.m. |
Concurrent Session 4b: Blood Coagulation in Health & Disease |
| 5:00 p.m. to 7:00 p.m. |
Poster Session 3 and Reception |
| 7:00 p.m. to 10:00 p.m. |
Vascular Discovery Council Celebration -- OFFSITE & Ticket is required to attend |
| Time | Activity |
|---|---|
| 7:30 a.m. | Registration |
| 7:30 a.m. to 8:30 a.m. | Morning Coffee |
| 7:30 a.m. to 8:30 a.m. | Industry Event #3 (in concurrent room) |
| 8:30 a.m. to 9:15 a.m. |
Plenary Session 5: Council Awards & Recognition |
| 9:15 a.m. to 9:30 a.m. | BREAK |
| 9:30 a.m. to 11:00 a.m. |
Plenary Session 6: Invited Lecture Series
9:30 Vascular Discovery Distinguished Lecture: The Assembly and Secretion of apoB Lipoproteins: Many Unanswered Questions After 60 Years of Research 10:00 Jeffrey M. Hoeg Arteriosclerosis, Thrombosis, and Vascular Biology Award for Basic Science and Clinical Research 10:30 PVD Mid-Career Award and Lecture |
| 11:00 a.m. to 11:15 a.m. | Closing Remarks / Adjourn 11:00 Kathleen Martin, PhD, Yale University School of Medicine |
2025 Speakers
Stanley L. Hazen, MD, PhD
Keynote Lecturer
Presentation Title: TBA
Dr. Stanley Hazen received clinical training in Internal Medicine and subspecialty training in Diabetes, Endocrinology and Metabolism from Barnes/Jewish Hospital, and a PhD in Biophysical Chemistry and Molecular Biology from Washington University School of Medicine, St. Louis, MO. He holds multiple leadership positions at the Cleveland Clinic including chair, Department of Cardiovascular & Metabolic Sciences, co-section head, Preventive Cardiology & Rehabilitation, and Director, Center for Microbiome & Human Health.
Dr. Hazen (H-index 159; citations >175,000) has published >500 articles in basic and clinical journals alike in the fields of cardiovascular disease (CVD), lipid metabolism and inflammation. He has made pioneering discoveries in mechanisms contributing to cardiovascular and inflammatory diseases, including fundamental studies linking defined oxidation pathways to CVD risk, diagnostics, and therapeutics; and the seminal discovery linking gut microbial pathways to CVD pathogenesis. His research in multiple areas has impacted clinical practice, and lays the foundation for both FDA- and EU-cleared diagnostic tests for CVD risk assessment in use worldwide. His research has also helped to spawn pharmaceutical development of CVD drugs in clinical trials.
Dr. Hazen is an elected fellow to the National Academy of Medicine, USA. He also is an elected fellow of the American Association for the Advancement of Science, and an elected member of the American Association of Physicians.
Henry N. Ginsberg, MD, FAHA
Vascular Discovery Distinguished Lecturer
Title: The Assembly and Secretion of apoB Lipoproteins: Many Unanswered Questions After 60 Years of Research
Friday, April 25, 2025 at 9:30 a.m.
Dr. Henry Ginsberg is the Irving Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons and Past Director of the Irving Institute for Clinical and Translational Research at the Columbia University Irving Medical Center in New York. He earned his medical degree at the State University of New York Downstate Medical Center in Brooklyn (1970), and completed training in internal medicine on the Boston University Service of the Boston City Hospital in Massachusetts (1970-1972). Dr. Ginsberg trained in Endocrinology and Metabolism at Stanford University (1972-74) under the tutelage of Gerald Reaven, one of the pioneers in studies of triglyceride metabolism, insulin resistance, and diabetes. He next completed a second postdoctoral fellowship in the laboratory of Virgil Brown and Daniel Steinberg (1976-78) where he was introduced to apolipoprotein B. In 1978, Dr. Ginsberg was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine. From 1985 until the present, he has been at Columbia.
During his time at Columbia, he has been PI of a T32 in Arteriosclerosis (1992-present), Director of an NCRR GCRC (1994-2006), and PI of an NCATS CTSA (2006-2017). His research, which was funded by NIH continually from 1980 to 2025, focused on the regulation of plasma lipid and lipoprotein levels, particularly the levels and metabolism of the apoB-containing lipoproteins, VLDL, IDL, and LDL, as well as HDL, in humans. He and his colleagues used radiolabeled lipoproteins and later, stably labeled amino acids and lipids to trace apoB, TG, and other apolipoproteins through the plasma, analyzing the data with compartmental models. He also has conducted studies in human and rodent hepatoma cells and in mouse models, focusing on the assembly of apoB with lipids to form VLDL and the role of insulin resistance and altered hepatic lipid metabolism on the assembly and secretion of VLDL. Dr. Ginsberg participated as a leader in many clinical trials and was the principal investigator on the Lipid Arm of the ACCORD trial (1998-2010). He has published over 300 peer-reviewed articles and more than 100 chapters and invited reviews. He has been an active member of ATVB committees, including as Chair of the Program Committee (1993-1996) and member, vice chair and chair of the Executive Committee (1999-2004). It was during the latter period that the leadership of the Arteriosclerosis and Thrombosis Councils merged with the Vascular Biology Working Group to created the ATVB Council. He has been recognized several times by AHA/ATVB, including being chosen to present the ATVB’s Lyman Duff Lecture in 2004 and the Council on Lifestyle and Cardiometabolic Health’s Robert Levy Lecture in 2014. Finally, Dr. Ginsberg, throughout his career, has had a small clinical practice caring for individuals with severe lipid disorders.
Jeffrey M. Hoeg Arteriosclerosis, Thrombosis, and Vascular Biology Award for Basic Science and Clinical Research
Sponsored by the Council on Arteriosclerosis, Thrombosis, and Vascular Biology
Friday, April 25, 2025 at 10:00 a.m.
More information still to come
PVD Mid-Career Award and Lecture
Friday, April 25, 10:30 a.m.
More information still to come
About this Meeting
This 2 ½-day meeting is sponsored by the Council on Arteriosclerosis, Thrombosis and Vascular Biology, the Peripheral Vascular Disease Council, and the Council on Genomic and Precision Medicine, in cooperation with and the Society for Vascular Surgery's Vascular Research Initiatives Conference.
Vascular Discovery 2025 will provide unique opportunities to meet with colleagues from around the world with wide-ranging research interests and expertise for the timely exchange of information about new and emerging scientific research in the areas of arteriosclerosis, thrombosis and vascular biology, peripheral vascular disease, vascular surgery research, genomics and precision medicine. We expect a broad representation from many disciplines and encourage young scientists to attend.
See the American Heart Association Policies and Guiding Values (PDF).
Target Audience
The conference will especially appeal to scientists and clinicians interested in:
- Allergy and Immunology
- Arteriosclerosis
- Biochemistry
- Biological Sciences
- Diabetes and Metabolism
- Functional Genomics
- Genetics
- Hematology
- Internal Medicine
- Molecular/Cellular Biology
- Nutrition
- Pathology
- Peripheral Artery Disease
- Pharmacology
- Physiology
- Vascular Surgery
- Thrombosis
- Vascular Biology
- Vascular Medicine
Learning Objectives
At the conclusion of this conference, participants will be able to:
- Discuss recent advances and emerging experimental models in ATVB and peripheral vascular diseases that target primary acquired diseases and/or secondary factors contributing to vascular-related disorders.
- Summarize findings from recent translational research or clinical trials and the impact for future treatment and/or management of vascular-related disorders.
- Describe best practices associated with ATVB scientific research and/or the management of patients with vascular-related diseases.